Teva Pharmaceutical Industries Limited: United Kingdom first to grant licence for Teva's ophthalmology biosimilar Ongavia (ranibizumab)?

MHRA today granted a licence for Ongavia (ranibizumab), a biosimilar to Lucentis*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic

Related Keywords

United Kingdom ,Switzerland ,British ,Swiss ,Frankg Holz ,Piotr Oleksy ,Federico Ricci ,Joachim Kiefer ,Richard Daniell ,Peterk Kaiser ,Steffen Schmitz Valckenberg ,John Lowe ,United Kingdom Medicines Healthcare Regulatory Agency ,Polpharma Biologics Group ,Study Group Efficacy ,Genentech Inc ,Formycon Group ,Experimental Eye Research ,Teva Pharmaceutical Industries Ltd ,Pharmaceutical Industries Ltd ,Executive Vice President ,Teva Europe Commercial ,Pharmaceutical Industries ,Group Efficacy ,Neovascular Age Related Macular Degeneration ,British Journal ,Private Securities Litigation Reform Act ,Quarterly Report ,Annual Report ,Teva ,Harmaceutical ,Industries ,Imited ,United ,Kingdom ,First ,Rant ,Licence ,Ophthalmology ,Biosimilar ,Ngavia ,Ranibizumab ,